The different clinical significance of EGFR mutations in exon 19 and 21 in non-small cell lung cancer patients of China

Neoplasma

Volumn 58, Issue 1, 2011, Pages 74-81

  Li, M ^a   Zhang, Q ^a   Liu, L ^a   Liu, Z ^a   Zhou, L ^b   Wang, Z ^a   Yue, S ^a   Xiong, H ^a   Feng, L ^a   Lu, S ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

EGFR; Mutation; Non small cell lung cancer

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; EGFR PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADULT; ARTICLE; CANCER PATIENT; CHINA; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA SEQUENCE; EXON; FEMALE; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; SEX DIFFERENCE; AGED; GENETICS; LUNG TUMOR; MIDDLE AGED; MUTATION; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79961120118     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2011_01_74     Document Type: Article

References (35)

1. Shigematsu, H., Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006; 118: 257-262. doi:10.1002/ijc.21496
2. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-346. doi:10.1093/ jnci/dji055
3. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305: 1163-1167. doi:10.1126/science.1101637
4. Scagliotti GV, Selvaggi G, Novello S, Hirsch FR. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 2004; 10: 4227s-4232s. doi:10.1158/1078-0432.CCR-040007
5. Yamamoto H, Toyooka S, Mitsudomi T. Impact of EGFR mutation analysis in non-small cell lung cancer. Lung Cancer 2009; 63: 315-321. doi:10.1016/ j.lungcan.2008.06.021
6. Uchida A, Hirano S, Kitao H, Ogino A, RAI K et al. Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation. Cancer Sci 2007; 98: 357-363. doi:10.1111/j.1349-7006.2007.00387.x
7. Molina JR, Adjei AA. The Ras/Raf/MAPK pathway. J Thorac Oncol 2006; 1: 7-9. doi:10.1097/01243894-200601000-00004
8. Lynch TJ, Bell DW, Sordella R, Gurubhaga-Vatula S, Okimoto RA et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139. doi:10.1056/NEJMoa040938
9. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500. doi:10.1126/science.1099314
10. Do H, Krypuy M, Mitchell PL, Fox SB, Dobrovic A. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 2008; 8: 142. doi:10.1186/1471-2407-8-142
11. Takano T, Ohe Y, Tsuta K, Fukui T, Sakamoto H et al. Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib. Clin Cancer Res 2007; 13: 5385-5390. doi:10.1158/1078-0432.CCR-07-0627
12. Tam IY, Chung LP, Suen WS, Wang E, Wong MC et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 2006; 12: 1647-1653. doi:10.1158/1078-0432.CCR-05-1981
13. Riely GJ, Pao W, Pham D, LI AR, Rizvi N et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006; 12: 839-844. doi:10.1158/1078-0432.CCR-05-1846
14. Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006; 12: 3908-3914. doi:10.1158/1078-0432.CCR-06-0462
15. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23: 2513-2520. doi:10.1200/ JCO.2005.00.992
16. VAN Zandwijk N, Mathy A, Boerrigter L, Ruijter H, Tielen I et al. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. Ann Oncol 2007; 18: 99-103. doi:10.1093/annonc/mdl323
17. Zhu JQ, Zhong WZ, Zhang GC, LI R, Zhang XC et al. Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals. Cancer Lett 2008; 265: 307-317. doi:10.1016/ j.canlet.2008.02.064
18. Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Janne PA et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009; 15: 5267-5273. doi:10.1158/1078-0432.CCR-09-0888
19. WU SG, Chang YL, Hsu YC, WU JY, Yang CH et al. Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern. Oncologist 2008; 13: 1276-1284. doi:10.1634/theoncologist.2008-0093
20. LI M, LIU L, LIU Z, YUE S, ZHOU L et al. The status of KRAS mutations in patients with non-small cell lung cancers from mainland China. Oncol Rep 2009; 22: 1013-1020.
21. Zhou L, Palais RA, Smith GD, Anderson D, Rowe LR et al. Enrichment and detection of rare alleles by means of snapback primers and rapid-cycle PCR. Clin Chem 2010; 56: 814-822. doi:10.1373/clinchem.2009.142034
22. KIM YT, KIM TY, LEE DS, Park SJ, Park JY et al. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. Lung Cancer 2008; 59: 111-118. doi:10.1016/j.lungcan.2007.08.008
23. ZHU CQ, DA CUNHA SANTOS G, DING K, SAKURADA A, CUTZ JC et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26: 4268-4275. doi:10.1200/JCO.2007.14.8924
24. JANG TW, OAK CH, CHANG HK, SUO SJ, JUNG MH. EGFR and KRAS mutations in patients with adenocarcinoma of the lung. Korean J Intern Med 2009; 24: 48-54. doi:10.3904/ kjim.2009.24.1.48
25. HUANG SF, LIU HP, LI LH, KU YC, FU YN et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004; 10: 8195-8203. doi:10.1158/1078-0432.CCR-04-1245
26. NA II, RHO JK, CHOI YJ, KIM CH, KOH JS et al. Clinical features reflect exon sites of EGFR mutations in patients with resected non-small-cell lung cancer. J Korean Med Sci 2007; 22: 393-399. doi:10.3346/jkms.2007.22.3.393
27. SASAKI H, ENDO K, KONISHI A, TAKADA M, KAWAHARA M et al. EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. Clin Cancer Res 2005; 11: 2924-2929. doi:10.1158/1078-0432.CCR-04-1904
28. SUGIO K, URAMOTO H, ONO K, OYAMA T, HANAGIRI T et al. Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer 2006; 94: 896-903. doi:10.1038/sj.bjc.6603040
29. Rosell R, Moran T, Queralt C, Porta R, Carde-Nal F et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-967. doi:10.1056/NEJMoa0904554
30. Sasaki H, Endo K, Takada M, Kawahara M, Kita-Hara N et al. L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer. Lung Cancer 2006; 54: 103-108. doi:10.1016/j.lungcan.2006.06.003
31. Gazdar AF, Shigematsu H, Herz J, Minna JD. Mutations and addiction to EGFR: the Achilles 'heal'of lung cancers? Trends Mol Med 2004; 10: 481-486.
32. Kumar A, Petri ET, Halmos B, Boggon TJ. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 2008; 26: 1742-1751. doi:10.1200/JCO.2007.12.1178
33. Carey KD, Garton AJ, Romero MS, Kahler J, Thomson S et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 2006; 66: 8163-8171. doi:10.1158/0008-5472.CAN-06-0453
34. Toyooka S, Matsuo K, Shigematsu H, Kosaka T, Tokumo M et al. The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. Clin Cancer Res 2007; 13: 5763-5768. doi:10.1158/1078-0432.CCR-07-0216
35. Yatabe Y, Mitsudomi T. Epidermal growth factor receptor mutations in lung cancers. Pathol Int 2007; 57: 233-244. doi:10.1111/j.1440-1827.2007.02098.x